Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

13. november 2026 oppdatert av: Finzelberg GmbH & Co. KG

The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults

The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.

Studieoversikt

Detaljert beskrivelse

This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.

Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.

Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.

Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.

Studietype

Intervensjonell

Registrering (Antatt)

78

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Cork, Irland
        • Atlantia Clinical Trials
        • Ta kontakt med:
    • RLP
      • Andernach, RLP, Tyskland, 56626
        • Finzelberg

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Be able to give written informed consent.
  2. Be between 18-70 years of age.
  3. BMI between 18.5 and 30.0 kg/m2
  4. Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
  5. Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.

Exclusion Criteria:

  1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.

  2. Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.

  3. Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)

  4. Participants that are habitual smokers or vapers

  5. High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day

  6. Has food allergies, or other issues with foods, that would preclude intake of the study products.

  7. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:

    1. Uncontrolled hypertension
    2. Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
    3. Diagnosed cognitive impairment
    4. Type I or II diabetes
    5. Clinically significant cardiovascular, liver and renal disease
    6. Diagnosed gastrointestinal conditions (IBD, coeliac disease)
  8. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:

    a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)

  9. Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:

    1. Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
    2. Products containing Sideritis, Sage, Thymus and Oregano
  10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

  11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Placebo supplement containing carrier material only

Placebo supplement containing carrier material only

Eksperimentell: Siderits

Sideritis supplement administered at an estimated daily dose

Sideritis scardica preparation (Greek Mountain Tea)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
Tidsramme: Baseline, day 1, day 7

Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)

Baseline, day 1, day 7

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cognitive performance during the test called Choice Reaction Time (CRT)
Tidsramme: Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%)

Baseline, day 1, day 7
Cognitive Performance: Rapid Visual Information Processing (RVIP)
Tidsramme: Baseline, day 1, day 7

Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits)

Baseline, day 1, day 7
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenation
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
Tidsramme: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels.

Baseline, day 1, day 7, approximately 150 to 240 minutes after administration

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. mars 2027

Studiet fullført (Antatt)

1. mai 2027

Datoer for studieregistrering

Først innsendt

30. oktober 2026

Først innsendt som oppfylte QC-kriteriene

13. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • FB_AF216

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.

IPD-delingstidsramme

Start date: Following completion of the study and publication of the primary study results.

End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.

Tilgangskriterier for IPD-deling

Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere